title: A single institution experience on 314 newly diagnosed advanced Hodgkin lymphoma patients: the role of ABVD in daily practice.
abstract: Based on the results of clinical trials, there is no global consensus on the optimal first-line therapy for patients with advanced Hodgkin lymphoma (HL) with both ABVD and BEACOPP currently being used. However, the results of clinical trials are usually better than those in daily practice. We thus describe here our experience on 314 advanced classical HL patients treated with ABVD at the Clinical Center of Serbia and associated centers between 1997 and 2008. The median follow-up for all patients was 91 months; the estimated 5-yr event-free survival was 62% and the 5-yr overall survival (OS) 76%. Multivariate Cox regression analysis revealed that patients with IPS ≥ 3 and extranodal disease involving more than one site have a poorer outcome. The data presented here show on overall improvement in outcome as compared to more previous data and illustrate the problems of treating advanced stage HL outside the setting of a clinical trial.
authors.affiliation: Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia.
authors.forename: Bosko
authors.initials: B
authors.lastname: Andjelic
authors.forename: Darko
authors.initials: D
authors.lastname: Antic
authors.forename: Ljubomir
authors.initials: L
authors.lastname: Jakovic
authors.forename: Milena
authors.initials: M
authors.lastname: Todorovic
authors.forename: Andrija
authors.initials: A
authors.lastname: Bogdanovic
authors.forename: Vladislava
authors.initials: V
authors.lastname: Djurasinovic
authors.forename: Jelena
authors.initials: J
authors.lastname: Bila
authors.forename: Biljana
authors.initials: B
authors.lastname: Mihaljevic
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols; D001761:Bleomycin / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008198:Lymph Nodes / Q000187:drug effects / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin
keywords: ABVD; advanced Hodgkin lymphoma; daily practice